Belviq litigation
The weight-loss drug Belviq was withdrawn from the market in 2020 after a long-term trial showed more cancers among patients taking it.
Free case review
What the lawsuits allege
The FDA requested the withdrawal of Belviq (lorcaserin) in February 2020 after a five-year safety trial showed a numerical imbalance in cancers, including pancreatic, colorectal, and lung cancer. The litigation alleges the manufacturer marketed the drug for years without resolving cancer signals seen in earlier animal studies.
Injuries named in the litigation
- Pancreatic cancer
- Colorectal cancer
- Lung cancer
Who may qualify
If you took Belviq or Belviq XR and were later diagnosed with pancreatic, colorectal, lung, or another qualifying cancer, you may have a claim. The review is free and confidential, and we will give you an honest answer either way. You pay attorney's fees only if we recover for you.
Call (888) 391‑1315 or use the form for a free, confidential review. You pay attorney's fees only if we recover for you.